Intriguingly, the “cytokine events” driven by sustained HRG-induced transactivation of HER2 via HER2/HER3 heterodimers were similar but not identical to those promoted by high levels of HER2 homodimers in HER2-overexpressing breast cancer cells. Here, ERBB3 is linked to breast cancer.